Drug intelligence / Profile preview

pb011

Development stage: Preclinical
Lead developer: Primo Biotechnology
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

PB011 is a radiopharmaceutical drug candidate under development for the treatment of neoplasms, primarily by Primo Biotechnology Co., Ltd. The therapeutic area is neoplasms, and the current highest global R&D status is preclinical. The development suggests potential use in cancer therapy, but no detailed mechanism of action, specific modality, or further clinical data (efficacy, toxicity, therapeutic class) is publicly available[1]. The company is advancing clinical trial plans for PB011, aiming to leverage Taiwan’s Category 2 new drug registration pathway to accelerate development[3].

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on pb011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pb011.

Explore the full profile